See more : Katsuragawa Electric Co., Ltd. (6416.T) Income Statement Analysis – Financial Results
Complete financial analysis of Chia Tai Enterprises International Limited (CAIHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chia Tai Enterprises International Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Marrone Bio Innovations, Inc. (MBII) Income Statement Analysis – Financial Results
- Parabellum Acquisition Corp. (PRBMW) Income Statement Analysis – Financial Results
- Mobiv Acquisition Corp (MOBVU) Income Statement Analysis – Financial Results
- Country Condo’s Limited (COUNCODOS.NS) Income Statement Analysis – Financial Results
- Aidemy Inc. (5577.T) Income Statement Analysis – Financial Results
Chia Tai Enterprises International Limited (CAIHF)
About Chia Tai Enterprises International Limited
Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment manufactures and sells CTC premix and CTC hydrochloride products, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brands. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of carburetors and automotive parts for automobile and motorcycle manufacturers. The company was incorporated in 1987 and is based in Central, Hong Kong. Chia Tai Enterprises International Limited is a subsidiary of Charoen Pokphand Foods Public Company Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.98M | 159.62M | 141.94M | 93.60M | 105.63M | 93.36M | 74.47M | 87.28M | 101.77M | 117.13M | 122.22M | 132.27M |
| Cost of Revenue | 140.21M | 120.34M | 107.29M | 68.70M | 76.52M | 66.11M | 52.42M | 56.06M | 67.81M | 79.45M | 85.45M | 92.66M |
| Gross Profit | 33.77M | 39.28M | 34.65M | 24.90M | 29.11M | 27.25M | 22.04M | 31.22M | 33.96M | 37.69M | 36.77M | 39.62M |
| Gross Profit Ratio | 19.41% | 24.61% | 24.41% | 26.61% | 27.56% | 29.19% | 29.60% | 35.77% | 33.37% | 32.17% | 30.09% | 29.95% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 195.00K | 211.00K |
| General & Administrative | 22.19M | 21.20M | 18.92M | 14.99M | 16.14M | 17.21M | 14.74M | 17.82M | 17.47M | 22.77M | 12.03M | 11.15M |
| Selling & Marketing | 16.11M | 13.11M | 10.87M | 8.61M | 9.12M | 7.06M | 6.69M | 6.48M | 6.71M | 7.28M | 5.87M | 6.15M |
| SG&A | 38.30M | 34.39M | 29.69M | 23.61M | 25.40M | 24.27M | 21.43M | 24.30M | 24.18M | 30.05M | 17.91M | 17.31M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.16M | 34.39M | 29.69M | 23.61M | 25.40M | 2.97M | 3.17M | 17.20M | 18.02M | 8.74M | 909.00K | 6.64M |
| Cost & Expenses | 178.51M | 154.73M | 136.99M | 92.31M | 101.92M | 69.08M | 55.59M | 73.25M | 85.83M | 88.19M | 86.36M | 99.29M |
| Interest Income | 1.15M | 368.88K | 75.75K | 327.09K | 606.36K | 533.00K | 193.00K | 401.00K | 904.00K | 1.12M | 590.00K | 125.00K |
| Interest Expense | 1.95M | 1.67M | 1.64M | 656.18K | 702.89K | 0.00 | 0.00 | 566.00K | 921.00K | 1.20M | 0.00 | 0.00 |
| Depreciation & Amortization | 6.39M | 6.79M | 7.41M | 4.53M | 4.49M | 4.83M | 5.11M | 5.35M | 5.39M | 5.44M | 5.13M | 5.62M |
| EBITDA | 11.29M | 11.69M | 12.34M | 5.82M | 8.40M | 7.81M | 5.73M | 12.27M | 15.17M | 13.07M | 24.06M | 34.40M |
| EBITDA Ratio | 6.49% | 7.33% | 8.69% | 6.22% | 7.95% | 8.37% | 7.69% | 14.06% | 14.91% | 11.16% | 18.80% | 20.19% |
| Operating Income | -4.54M | 4.89M | 4.95M | 1.29M | 3.71M | 2.99M | 613.00K | 6.92M | 9.78M | 7.63M | 17.84M | 21.09M |
| Operating Income Ratio | -2.61% | 3.06% | 3.49% | 1.38% | 3.51% | 3.20% | 0.82% | 7.93% | 9.61% | 6.52% | 14.60% | 15.94% |
| Total Other Income/Expenses | 7.48M | -2.75M | 20.05M | 3.44M | 16.27M | 21.83M | 18.46M | 6.70M | 5.26M | 20.19M | 16.60M | 7.24M |
| Income Before Tax | 2.94M | 4.13M | 25.02M | 4.73M | 19.97M | 24.81M | 19.07M | 13.62M | 15.04M | 27.83M | 35.27M | 33.10M |
| Income Before Tax Ratio | 1.69% | 2.59% | 17.63% | 5.06% | 18.91% | 26.58% | 25.61% | 15.61% | 14.78% | 23.76% | 28.86% | 25.03% |
| Income Tax Expense | 1.06M | 1.51M | 4.61M | 1.16M | 1.85M | 1.61M | 1.36M | 2.56M | 3.37M | 4.23M | 1.89M | 8.54M |
| Net Income | 2.55M | -6.69M | 19.50M | 16.26M | 15.89M | 21.16M | 16.35M | 8.06M | 8.18M | 19.43M | 27.79M | 17.71M |
| Net Income Ratio | 1.47% | -4.19% | 13.74% | 17.37% | 15.04% | 22.67% | 21.95% | 9.23% | 8.04% | 16.59% | 22.74% | 13.39% |
| EPS | 0.01 | -0.03 | 0.08 | 0.06 | 0.06 | 0.08 | 0.06 | 0.03 | 0.03 | 0.09 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | -0.03 | 0.08 | 0.06 | 0.06 | 0.08 | 0.06 | 0.03 | 0.03 | 0.09 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 236.20M | 218.40M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 253.33M | 236.21M | 218.41M | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports